3rd Quarter - Report

GENENTECH, INC for GENENTECH INC

Firm
Client
Income
—
Expenses
$570,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

House Concurrent Resolution 312 FY09 Budget Resolution Senate Concurrent Resolution 70 FY09 budget Resolution Comparative Effectiveness H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 2638 (110th)

Health Issues HCR

H.R. 6331 Medicare Improvements for Patients and Providers Act of 2008 S. 3101 Improvements for Patients and Providers Act of 2008 H.R. 5629 Pathway for Biosimilars Act

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO); White House Office

Bills named: H.R. 6331 (110th), H.R. 5629 (110th), S. 3101 (110th)

Taxation/Internal Revenue Code TAX

Tax legislation/R&D tax credit

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; White House Office; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA)

Copyright/Patent/Trademark CPT

S. 1145, Patent Reform Act of 2007, entire bill H.R. 1908, Patent Reform Act of 2007, entire bill S. 3600, Patent Reform Act of 2008 HR 5629 - Pathways to Biosimilars Act S.623 - Access to Life-Saving Medicine Act

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE

Bills named: S. 1145 (110th), H.R. 1908 (110th), S. 3600 (110th), H.R. 5629 (110th), S. 623 (110th)

Medicare/Medicaid MMM

H.R. 5480, Medicare Funding Warning Response Act of 2008 H.R. 1424, Emergency Economic Stabilization Act of 2008 S. 2029, Physician Payments sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008Comparative Effectiveness Comparative Effectiveness H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008 S. 3101, Medicare Improvements for Patients and Providers Act of 2008

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); White House Office; Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5480 (110th), S. 3101 (110th), S. 2029 (110th), H.R. 6331 (110th), H.R. 1424 (110th), S. 2662 (110th)

Pharmacy PHA

H.R. 1038, Acces to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act H.R. 4911, Human Growth Hormone Restriction Act of 2007 H.R. 5839, Safeguarding America's Pharmaceuticals Act S. 1505 Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics S. 877, Controlling Abuse of Prescription Drugs Act of 2007

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); White House Office; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 877 (110th), S. 2029 (110th), H.R. 5839 (110th), S. 623 (110th), S. 1695 (110th), H.R. 5629 (110th), H.R. 4911 (110th), S. 1505 (110th), H.R. 1956 (110th), S. 596 (110th), H.R. 1038 (110th)

Medical/Disease Research/Clinical Labs MED

LHHS Appropriations (CMS and comparative effectiveness related matters)

LobbyistCovered position, as disclosed
DAVID B BURT New —
WALTER MOORE —
PETER JOSEPH MULLER —
HEIDI L WAGNER —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.